Merck Serono's Kuvan heads CHMP positive opinion list
This article was originally published in Scrip
Executive Summary
The first drug therapy for phenylketonuria,Merck Serono's Kuvan (sapropterin dihydrochloride), was among three products granted positive opinions on initial marketing from the EU's CHMPat its latest meeting on September 22nd-25th.